Enterolactone has stronger effects than enterodiol on ovarian cancer

BACKGROUND: Ovarian cancer is one of the three leading gynecological malignancies, characterized by insidious growth, highly frequent metastasis, and quick development of drug resistance. As a result, this disease has low 5-year survival rates. Estrogen receptor inhibitors were commonly used for the...

詳細記述

保存先:
書誌詳細
出版年:J Ovarian Res
主要な著者: Liu, Huidi, Liu, Jianrui, Wang, Siwen, Zeng, Zheng, Li, Ting, Liu, Yongfang, Mastriani, Emilio, Li, Qing-Hai, Bao, Hong-Xia, Zhou, Yu-Jie, Wang, Xiaoyu, Hu, Sijing, Gao, Shan, Qi, Yingying, Shen, Zhihang, Wang, Hongyue, Yu, Miao, Gao, Tingting, Johnston, Randal N., Liu, Shu-Lin
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2017
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5525236/
https://ncbi.nlm.nih.gov/pubmed/28738876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-017-0346-z
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料